Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
| Revenue (TTM) | $38.09B |
| Gross Profit (TTM) | $27.39B |
| EBITDA | $17.27B |
| Operating Margin | 35.50% |
| Return on Equity | 91.50% |
| Return on Assets | 8.67% |
| Revenue/Share (TTM) | $70.68 |
| Book Value | $21.62 |
| Price-to-Book | 18.78 |
| Price-to-Sales (TTM) | 5.88 |
| EV/Revenue | 6.9 |
| EV/EBITDA | 14.92 |
| Quarterly Earnings Growth (YoY) | 64.90% |
| Quarterly Revenue Growth (YoY) | 9.50% |
| Shares Outstanding | $540.63M |
| Float | $539.16M |
| % Insiders | 0.23% |
| % Institutions | 85.02% |
Volatility is currently contracting
Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.
Subscribers to Schaeffer's Weekend Trader options recommendation service received this AMGN commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.
Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically meaningful improvement in the primary endpoint, the change from baseline in ESSDAI at week 48.
Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yields, raising 2026 guidance and improving earnings estimates.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMGN and any ticker you trade — then tracks every position and per-strategy win rate.
